Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.

about

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.

Item

http://www.wikidata.org/entity/Q43243759

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Resource utilization and cost ...... early breast cancer patients.

@en

Resource utilization and cost ...... early breast cancer patients.

@nl

type

Item

label

Resource utilization and cost ...... early breast cancer patients.

@en

Resource utilization and cost ...... early breast cancer patients.

@nl

prefLabel

Resource utilization and cost ...... early breast cancer patients.

@en

Resource utilization and cost ...... early breast cancer patients.

@nl

P1476

Resource utilization and cost ...... n early breast cancer patients

@en

P2093

Alberto Farolfi

http://www.w3.org/2001/XMLSchema#string

Alessio Schirone

http://www.w3.org/2001/XMLSchema#string

Carla Masini

http://www.w3.org/2001/XMLSchema#string

Davide Gallegati

http://www.w3.org/2001/XMLSchema#string

Mattia Altini

http://www.w3.org/2001/XMLSchema#string

Paolo Silimbani

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers

Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Automated preparation of chemotherapy: quality improvement and economic sustainability.

P304

81343-81349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18527

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elisabetta Petracci

P577

2017-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29113393

http://www.w3.org/2001/XMLSchema#string

P932

5655288

http://www.w3.org/2001/XMLSchema#string